Aerovate Therapeutics (AVTE) Stock Chart & Stock Price History $7.38 +0.53 (+7.74%) As of 08/21/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aerovate Therapeutics Stock Price Performance The Aerovate Therapeutics (AVTE) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 88.54%, with a year-to-date return of -92.04%. In the past month, the stock has decreased 15.07%, reflecting recent market activity. As of the latest close, Aerovate Therapeutics traded at $7.36 with a market cap of $213.33 million and volume of 84,262 shares. Receive AVTE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+9.01%1 Month Performance-15.07%3 Month Performance-1.47%Year-To-Date Performance-92.04%1 Year Performance-88.54% AVTE Stock Chart for Friday, August, 22, 2025 AVTE Chart by TradingView Aerovate Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$7.36$7.38+0.27%$7.45$6.71100,416 shs$213.91 million08/21/2025$7.36$7.36$7.64$7.2884,262 shs$213.33 million08/20/2025$7.50$7.36-1.87%$7.64$7.2884,262 shs$213.33 million08/19/2025$7.36$7.50+1.90%$7.62$7.25106,061 shs$217.39 million08/18/2025$7.36$7.36$7.39$6.67186,080 shs$213.33 million08/15/2025$7.33$6.77-7.64%$7.76$6.7179,151 shs$196.23 million08/14/2025$7.39$7.33-0.81%$7.40$7.0970,945 shs$212.46 million08/13/2025$7.40$7.39-0.14%$8.00$7.2979,258 shs$214.20 million08/12/2025$7.49$7.40-1.20%$7.72$7.2169,957 shs$214.49 million08/11/2025$7.49$7.49$7.58$7.1277,779 shs$217.10 million Get the Latest News and Ratings for AVTE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$7.83$7.32-6.51%$8.00$7.20116,595 shs$212.17 million08/07/2025$7.94$7.83-1.39%$8.13$7.7899,183 shs$226.95 million08/06/2025$6.89$7.94+15.24%$8.15$7.18127,026 shs$230.14 million08/05/2025$6.89$6.89$7.56$6.87143,073 shs$199.71 million08/04/2025$6.89$6.89$7.56$6.87143,073 shs$199.71 million08/01/2025$6.88$7.19+4.51%$7.31$6.77143,540 shs$208.40 million07/31/2025$7.75$6.88-11.23%$7.74$6.69146,854 shs$199.42 million07/30/2025$7.75$7.75$8.33$7.74117,673 shs$224.63 million07/29/2025$8.28$7.75-6.40%$8.33$7.74117,673 shs$224.63 million07/28/2025$8.28$8.28$8.46$7.9074,574 shs$240.00 million07/25/2025$8.71$8.33-4.36%$8.71$8.29130,060 shs$241.45 million07/24/2025$8.98$8.71-3.01%$9.06$8.50123,799 shs$252.46 million07/23/2025$8.69$8.98+3.34%$9.00$8.42153,280 shs$260.29 million07/22/2025$9.47$8.69-8.24%$9.57$8.55121,393 shs$251.88 million07/21/2025$9.47$9.47$9.70$9.36222,632 shs$274.49 million Related Companies Urogen Pharma Stock Chart Mineralys Therapeutics Stock Chart Immunome Stock Chart CorMedix Stock Chart Oric Pharmaceuticals Stock Chart atai Life Sciences Stock Chart Oculis Stock Chart Valneva Stock Chart Mind Medicine (MindMed) Stock Chart Immatics Stock Chart Receive AVTE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AVTE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access